Cutaneous malignant melanoma 1

Common Name(s)

Cutaneous malignant melanoma 1

Malignant melanoma is a neoplasm of pigment-producing cells called melanocytes that occurs most often in the skin, but may also occur in the eyes, ears, gastrointestinal tract, leptomeninges, and oral and genital mucous membranes (summary by {55:Habif, 2010}). Genetic Heterogeneity of Susceptibility to Cutaneous Malignant Melanoma The locus for susceptibility to familial cutaneous malignant melanoma-1 (CMM1) has been mapped to chromosome 1p36. Other CMM susceptibility loci include CMM2 ({155601}), caused by variation in the CDKN2A gene ({600160}) on chromosome 9p21; CMM3 ({609048}), caused by variation in the CDK4 gene ({123829}) on chromosome 12q14; CMM4 ({608035}), mapped to chromosome 1p22; CMM5 ({613099}), caused by variation in the MC1R gene ({155555}) on chromosome 16q24; CMM6 ({613972}), caused by variation in the XRCC3 gene ({600675}) on chromosome 14q32; CMM7 ({612263}), mapped to chromosome 20q11; CMM8 ({614456}), caused by variation in the MITF gene ({156845}) on chromosome 3p13; CMM9 ({615134}), caused by variation in the TERT gene ({187270}) on chromosome 5p15; and CMM10 ({615848}), caused by mutation in the POT1 gene ({606478}) on chromosome 7q31. Somatic mutations causing malignant melanoma have also been identified in several genes, including BRAF ({164757}), STK11 ({602216}), PTEN ({601728}), TRRAP ({603015}), DCC ({120470}), GRIN2A ({138253}), ZNF831, BAP1 ({603089}), and RASA2 ({601589}). A large percentage of melanomas (40-60%) carry an activating somatic mutation in the BRAF gene, most often V600E ({164757.0001}) ({32:Davies et al., 2002}; {90:Pollock et al., 2003}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous malignant melanoma 1" for support, advocacy or research.

Logo
Melanoma International Foundation

The mission of the Melanoma International Foundation is to develop personalized strategies with patients so they may live longer, better lives.

Last Updated: 29 Jun 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous malignant melanoma 1" for support, advocacy or research.

Logo
Melanoma International Foundation

The mission of the Melanoma International Foundation is to develop personalized strategies with patients so they may live longer, better lives.

http://www.melanomainternational.org

Last Updated: 29 Jun 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Cutaneous malignant melanoma 1" returned 10 free, full-text research articles on human participants. First 3 results:

Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma.
 

Author(s): Figen Barut, Perihan Udul, Furuzan Kokturk, Nilufer Onak Kandemir, Sevinc Hallac Keser, Sukru Oguz Ozdamar

Journal: Kaohsiung J. Med. Sci.. 2016 Oct;32(10):494-500.

 

The evidence that PITX1 (pituitary homeobox 1) is a significant tumor suppressor in human cancer remains largely circumstantial, but it clearly warrants further study as little is known about the tumor-inhibitory roles of PITX1 in cutaneous malignant melanoma. The aims of this study ...

Last Updated: 31 Dec 1969

Go To URL
Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma.
 

Author(s): Hanna Siiskonen, Mari Poukka, Kristiina Tyynelä-Korhonen, Reijo Sironen, Sanna Pasonen-Seppänen

Journal:

 

Hyaluronan is an extracellular matrix glycosaminoglycan involved in invasion, proliferation and metastasis of various types of carcinomas. In many cancers, aberrant hyaluronan expression implicates disease progression and metastatic potential. Melanoma is an aggressive skin cancer. ...

Last Updated: 31 Dec 1969

Go To URL
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
 

Author(s): Mia Spugnardi, Stella Tommasi, Reinhard Dammann, Gerd P Pfeifer, Dave S B Hoon

Journal: Cancer Res.. 2003 Apr;63(7):1639-43.

 

Recent findings have shown the inactivation of a Ras effector homologue gene referred to as the Ras association domain family 1 (RASSF1) gene, which is a potential human tumor suppressor gene located on chromosome 3p21.3. Hypermethylation of the CpG island promoter region of a major ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Cutaneous malignant melanoma 1" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 18 Dec 2017

Go to URL
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
 

Status: Recruiting

Condition Summary: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors; Melanoma

 

Last Updated: 18 Dec 2017

Go to URL
Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma
 

Status: Not yet recruiting

Condition Summary: Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7

 

Last Updated: 5 Jan 2018

Go to URL